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Several techniques are under development to diagnose oesophageal adenocarcinoma at an earlier stage. We have demonstrated the
potential of Raman spectroscopy, an optical diagnostic technique, for the identification and classification of malignant changes.
However, there is no clear recognition of the biochemical changes that distinguish between the different stages of disease. Our aim is
to understand these changes through Raman mapping studies. Raman spectral mapping was used to analyse 20-mm sections of tissue
from 29 snap-frozen oesophageal biopsies. Contiguous haematoxylin and eosin sections were reviewed by a consultant pathologist.
Principal component analysis was used to identify the major differences between the spectra across each map. Pseudocolour score
maps were generated and the peaks of corresponding loads identified enabling visualisation of the biochemical changes associated
with malignancy. Changes were noted in the distribution of DNA, glycogen, lipids and proteins. The mean spectra obtained from
selected regions demonstrate increased levels of glycogen in the squamous area compared with increased DNA levels in the
abnormal region. Raman spectroscopy is a highly sensitive and specific technique for demonstration of biochemical changes in the
carcinogenesis of Barrett’s oesophagus. There is potential for in vivo application for real-time endoscopic optical diagnosis.
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Despite advances in diagnosis and therapy, oesophageal adeno-
carcinoma remains an aggressive and usually lethal tumour (Zhang
et al, 2005). Given the poor prognosis associated with the disease, a
better understanding the pathogenesis and the factors associated
with increased risk is essential. Also, strategies for prevention of
oesophageal adenocarcinoma are hotly contested. The increased
incidence of oesophageal adenocarcinoma is mirrored by similar
rise in the incidence of Barrett’s oesophagus (Prach et al, 1997).
Barrett’s oesophagus a premalignant condition is characterised
by columnar mucosa, specifically intestinal metaplasia (IM)
(Hamilton et al, 1988; Weinstein and Ippoliti, 1996).
Raman spectroscopy an optical diagnostic technique has been
recognised as a valuable analytical tool in biological and medical
research. It depends on an energy shift due to interaction with
vibrational modes of molecules. The Raman spectrum is a direct
function of the molecular composition of the tissue and provides a
fingerprint of the tissue (Crow et al, 2003; Koljenovic et al, 2004;
Stone et al, 2004).
During the past decade, progress in Raman spectroscopic
instrumentation has increased the sensitivity of the measurement
to such a degree that the acquisition of high-quality spectral data
from biological tissue and cells is possible. The greatest benefit of
this technique lies in its high sensitivity to subtle molecular and
biochemical changes, as well as its capability for noninvasive
sensing (Haka et al, 2002; Mantsch et al, 2002; Shafer-Peltier et al,
2002).
In previous studies, we have demonstrated the potential of
Raman spectroscopy for the identification and classification of
malignant changes in oesophagus. Raman spectroscopy was used
to analyse 87 oesophageal biopsies from 44 patients. Spectral
results were correlated with the consensus opinion of three
gastrointestinal pathologists using multivariate statistical analysis
(Kendall et al, 2003). However, there was no clear recognition of
the biochemical changes that distinguished between the different
stages of malignant progression. Our aim in this study was to
understand these changes through Raman mapping and to attain
direct biochemical information on Barrett’s oesophagus, which is
novel in this field.
This study utilises near-infrared Raman Spectroscopy, a highly
specific optical analysis technique, to build robust spectral,
biochemical diagnostic models of oesophageal pathologies. In
doing so we will further our understanding of carcinogenesis in
these tissues.
MATERIALS AND METHODS
Ethical approval for this study was obtained from the Gloucester-
shire Local Research Ethics Committee. Informed consent was
obtained from the patients at routine upper gastrointestinal
endoscopy for surveillance of Barrett’s oesophagus, chronic
reflux symptoms and with suspected malignancy. Barrett’s
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soesophagus was defined as the presence of columnar mucosa
in the distal oesophagus of any length with IM on biopsy (Sharma
et al, 1998). Patient demographics, including age and sex were
noted.
In total, 29 samples collected from 22 patients were included in
the study. The biopsies collected were snap-frozen in liquid
nitrogen after mounting them on acetate paper. A consultant
gastrointestinal pathologist who was blinded to identity and
symptoms of the patient examined haematoxylin and eosin
sections obtained from the frozen samples. The biopsy samples
were classified as normal squamous, IM, low-grade dysplasia
(LGD), high-grade dysplasia (HGD) and adenocarcinoma. Mixed
samples with two pathologies were included in the study, which
would mimic in vivo application. Owing to the focal change of
mucosa often the scanned area will have heterogeneous pathology.
A 20-mm contiguous section for Raman mapping, mounted on
calcium fluoride, was left uncontaminated thus providing an
approximation to an in vivo approach.
Raman spectral measurement
Raman spectra were measured with a highly sensitive Renishaw
Raman System 1000s spectrometer optimised to provide rapid
acquisition of high-quality tissue spectra. A diode laser with
830nm incident light was used for excitation of the tissue. The
spectrometer was connected to a microscope fitted with a Leica
(NA 0.5)  50 ultra long working distance objective lens and
motorised stage to allow micro positioning of small tissue samples.
A single 300linesmm
 1 grating was used to disperse the collected
light and a charged coupled device detector measured the signal at
each wavelength.
In total, 25000 spectra were measured from the sections on
calcium fluoride slides. The spectra were collected at 100-mm steps
across whole sections to provide information about global changes
in the specimen. The contiguous haematoxylin and eosin section
image captured by a digital camera mounted microscope was used
to verify the different areas of dysplasia. The consultant
pathologist compared these images with the white light images
from the calcium fluoride section.
Spectral analysis
Analysis was performed using Matlab and the PLS toolbox
(Eigenvector Technologies, Manson, Washington, USA), generat-
ing principal components, which were used to identify the major
differences between the spectra across each map. Pseudocolour
maps of the principal component scores have been generated, and
the peaks of the corresponding loads identified, enabling
visualisation of the biochemical changes associated with malig-
nancy (Pelletier, 2003). Reference spectra were obtained of
glycogen, actin, triolein, DNA, collagen type 1, oleic acid
(purchased from Sigma-Aldrich, Gillingham, UK).
Mean spectra from regions of interest were plotted for
comparison and identification of spectral differences. Peak
assignments of these mean spectra were also identified. Relative
concentrations of different biochemical constituents were obtained
by mathematical fit to mean spectra. This was performed as
follows:
The PLS-toolbox
s (Eigenvector) for Matlab
s was adapted for
use with the data in these studies. The fitting of the mean spectra of
the biochemical constituents to the mean spectra of the different
regions of interest from the tissue specimens was performed with
ordinary least squares analysis. To optimise this process and
remove any spectral offset the first derivative of each of the spectra
was calculated using a Savitsky-Golay filter.
This fitting process is explained simply below. We begin by
describing the measured tissue spectrum as a sum of the
constituent spectra multiplied by their concentrations plus a
residual or error. This leads to
X ¼ cS þ E
where S is the matrix of spectral components, c is the matrix of
concentrations to be predicted and X is the measured spectra. This
can be used to provide a ‘best fit’ of the spectral components or
basis spectra found within the measured spectra. The assumption
is made that the residual E is minimised (i.e., least square of the
residual) and that the spectral components selected are the major
constituents of the spectra.
c ¼
ðX   EÞ
S
The disadvantage with this technique is that any colinearity in the
components selected will skew the fit. An example being amino
acids and the proteins containing them being used in the same
model. Furthermore, if components are not included the omitted
variable bias can introduce some errors in the fit. (Sowa et al,
2006) Observation of the residual E enables the quality of the fit
to be observed and any remaining features of the spectra to be
included in the next iteration of the model.
RESULTS
In total, 29 samples with different pathologies were studied from
22 patients with male to female ratio of 26:4. The pathologies with
normal squamous and adenocarcinoma and normal squamous and
LGD constituted 24% each, normal squamous and HGD were 33%,
normal squamous and IM were 14% and the rest were normal
squamous and squamous dysplasia (Table 1).
Figure 1 shows the haematoxylin and eosin section of the
normal squamous and HGD (A) and normal squamous and
adenocarcinoma (B) sections. The pseudocolour maps of PC scores
and the corresponding loads (generated from the specimen during
spectral analysis) of normal squamous and HGD illustrate the
biochemical variation in the tissue. These are shown in Figure 2.
The concentration distribution of different biochemical constitu-
ents in the various principal component score maps, vary from
high-intensity colour red to low-intensity blue.
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Figure 1 Haematoxylin and eosin stained sections with pathology
labelled. (A) Regions 1 and 2 normal squamous and regions 3 and 4 HGD.
(B) Region 1 normal squamous and regions 2, 3 and 4 adenocarcinoma.
Table 1 Pathologies of different samples
NSq and
IM
NSq and
LGD
NSq and
HGD
NSq and
adeno
NSq and
SqDy
47 1 0 7 1
Adeno, adenocarcinoma; HGD, high-grade dysplasia; IM, intestinal metaplasia; LGD,
low-grade dysplasia; NSq, normal squamous; SqDy, squamous dysplasia.
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sThe first score map of normal squamous and HGD section shows
the highest variation across the map between tissue and calcium
fluoride slide. Peak assignment of the other following loads
demonstrates further variation in the tissue distribution of DNA
(deoxyribonucleic acid), glycogen, lipids and proteins.
For example in load 3, DNA peaks can be demonstrated at 722,
752, 782 and 1663cm
 1 and peaks at 820, 884, 1223, 1278 and
1663cm
 1 correspond to proteins, including collagen I. The
corresponding score shows variation in the DNA and proteins
across the sample. Similarly, in load 6 peaks at 852 and 918cm
 1
correspond to glycogen and 750 and 918cm
 1 to lactic acid. Almost
all inverted peaks in PC 6 load corresponds to DNA,
which is concentrated in dysplastic area (Figure 1A). As the number
of principal components increases more subtle variations can be
seen. The variation in the lipids and DNA can be demonstrated
across the sample in PC load 8 and its corresponding score.
Figure 3 shows the score map from the third principal
component (A) with the mean spectra from the selected four
regions (B). Spectral differences were demonstrated between the
selected regions, for example; glycogen peaks are seen at 853, 937
and 1333cm
 1 and DNA peaks can be clearly demonstrated at 719,
755 and 781cm
 1. The mean spectra from the selected regions
were analysed for variation in the biochemical composition of the
tissue (C). Following mathematical least squares fit, marked
variation in the distribution of different biochemical constituents
were seen; such as glycogen, DNA, oleic acid and collagen I across
the tissue sample. DNA, oleic acid, collagen I and actin are
predominantly seen in the region of HGD and glycogen in the
normal squamous tissue.
An additional example of the distribution of various biochem-
ical constituents is shown in Figure 3D–F. Figure 1B shows the
section of normal squamous and adenocarcinoma with patholo-
gical distribution. The corresponding third principal component
score shown in Figure 3D shows clear differentiation in the
subpathologies, which has been delineated by colour contrast in
pseudocolour map. The score map shows variation in the DNA and
glycogen content across the sample. The mean spectra from the
selected regions (1, 2, 3 and 4 in Figure 3D and F) were analysed to
understand the biochemical changes associated in these regions.
The analysis was carried out in a similar way to the previous
sample and distinct variation was noted in the distribution of
glycogen, DNA, actin and oleic acid. In Figure 3E the spectral
difference for glycogen is more pronounced in region 1. The
glycogen peaks at 481, 853, 937 and 1048cm
 1 in the mean
spectrum of region 1 can be clearly demonstrated. On the contrary
the DNA triplets at 720, 729 and 748cm
 1 are well seen in the
spectra of regions 2, 3 and 4. The biochemical distribution plot
shows increase distribution of DNA, actin and oleic acid in
dysplastic glandular regions (2, 3 and 4 regions in Figure 3D–F).
DISCUSSION
Better understanding of the carcinogenesis of Barrett’s oesophagus
is an essential step in targeting the lesion and improving the
survival. Currently, endoscopy with biopsy during surveillance,
or in suspected patients, is the gold standard for diagnosis of
malignancy. In spite of various diagnostic methods and some
surveillance programmes survival has not improved in last decade.
The potential of present surveillance programmes to improve
detection of adenocarcinoma at early stage has been questioned by
many studies (Reid et al, 1988; van Sandick et al, 1998; Macdonald
et al, 2000; Montgomery et al, 2001).
To improve mortality it is vital to diagnose the lesion at an early
stage where there are only biochemical changes without significant
architectural changes. A new diagnostic technique, which can
facilitate this application, is valuable in future.
Various methods have been adopted to understand the
molecular biology of cancer tissue. Most of these concentrate on
DNA changes; however, little attention has been given to under-
stand the other biochemical changes in the tissue (Jankowski et al,
1999; Doak et al, 2003). By understanding and quantifying the
biochemical changes during neoplastic progression it may be
possible to detect the abnormal lesion before morphological
changes can occur.
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Figure 2 First eight pseudocolour principal component score maps and corresponding loads for the normal squamous and HGD sample (H&E stained
section Figure 1A). PC 1 top left to PC 8 bottom right.
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sFor the development of new diagnostic methods for detection of
tissue states in vivo, it is important to understand the spectral
features of pure individual components of tissues; that means cells
and subcellular components. Raman spectroscopy is still evolving
at this stage.
Recent studies shows that Raman microspectroscopy has been
applied to record complete spectral maps of freeze-dried cells as
well as living cells in media without the need for any fixing
technique before the mapping. The resulting spectra showed the
localisation of the nucleus, organelles and the membrane (Kraft
et al, 2003). Raman spectroscopy is more often associated with the
determination of molecular structure and with qualitative analysis;
as an example, the conformational characterisation of natively
unfolded proteins through a simple band fitting of the amide I
region has been recently described (Maiti et al, 2004). There have
also been numerous applications of Raman spectroscopy for the
quantitative analysis of sample composition, the most relevant
application fields being clinical (Mc Laughlin et al, 2002; Pelletier,
2003). It needs further studies to unravel all the information or
data present in the Raman spectrum.
Our results show Raman spectroscopy is a true indicator of
biochemical changes in the tissue. The Raman effect is due to an
energy shift due to interaction with molecular vibration modes, a
Raman spectrum reflects the signature of that molecule. Overall we
know the major changes in the cell such as increase in the DNA,
however, delicate variation of different components (such as
sugars, lipids, proteins and amino acids) needs attention. The
subtle variations in the spectral peaks can confer ample
biochemical information from the tissue.
The changes in the distribution of DNA, lipids and proteins in
the cells during the process of carcinogenesis could be early
markers in detection of high-risk patients before morphological
changes occur. This study is a significant first step towards
establishing these biochemical changes. By further understanding
the carcinogenesis process it would help us to improve the
diagnostic techniques, thus improving the survival. These pre-
liminary results need further studies to confirm the results and
to study more biochemical components. This will also need to be
validated by different centres, and inter and intraobserver
variability should be addressed.
Possible future applications of Raman spectroscopy include an
in vivo endoscopic probe during surveillance, thus identifying high
yield areas and eliminating the need for random biopsies. This
may reduce sampling error and decrease or eliminate the need for
biopsy that adds to the cost of the procedure. The Raman spectrum
is a direct function of the molecular composition of the tissue and
can therefore also be used to give a truly objective measure of
pathology. Hence Raman spectroscopy can be potentially used as
pathological tool in validating the diagnoses, identifying the
margins in curative resection and lymph nodes.
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